Given there are serious limitations to pharmaceutical cannabinoid medications, it’s clear that the problem lies in the insurance system that has yet to evolve alongside patients’ needs and medical science. There is a clear disconnect when insurance companies can cover synthetic cannabinoid drugs but can’t acknowledge the medicinal value of whole cannabis compounds. Then again, the issue circles back to the federal government.
New Jersey’s THC beverage market is heading into the most consequential stretch of its short…
Mormon Wives star Mikayla Matthews says medical cannabis was “literally life-changing” for her nerve pain…
Chains reorder every two weeks and earn twice the discounts. Independents stock the same breadth…
We head to Canna Country Farms in Humboldt for Legendary Strains to discover the Ocimene…
Cannabis advocates should take the lesson here too. The industry doesn't need to inflate its…
Twenty patient associations from across northeastern Brazil are meeting in Fortaleza this month, inside a…